Lode-Star rescinds Sapir asset purchase; reinstates $2.2M debt, converts $2.6M debt into 70.3M shares

FinTrade Sherpa, Inc.

Rescinded Sapir Pharmaceuticals asset purchase and royalty agreements on June 6, 2022; neither party has further obligations.
Reinstated ~$2.224 million in accrued unpaid debt owed to Lode Star Gold (LSG) that was previously forgiven in January 2022.
Converted $2,601,207.55 in debt from three related parties into 70,302,906 common shares at $0.037 per share.
LSG received 62,769,918 shares; CEO Mark Walmesley received 6,372,405 shares for his debt; Lonnie Humphries got 1,160,583 shares.
Rescission due to inability to develop EGCG business; no preferred stock had been issued under the original agreement.

item 1.02 item 1.01 item 2.01 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.